Tools
Enthesopathies
Introduction
Entheses serve as sites of bone insertion for tendons and ligaments, and enthesopathies encompass pathologic processes affecting these structures.[1] Although their classification remains debated, researchers commonly describe 2 primary types: fibrous and fibrocartilaginous. Fibrous entheses anchor directly to the periosteum, whereas fibrocartilaginous entheses attach without periosteal involvement.[2]
Most entheses are located outside the joint capsule, with notable exceptions at the sacroiliac, sternoclavicular, and distal interphalangeal joints.[3] These structures contribute to joint stability and transmit mechanical forces.[4] A distinctive feature involves their relatively low vascularity.[2] Enthesitis, a subtype of enthesopathy, refers to inflammation affecting the tendon and ligament insertion sites on bone.[1] Enthesitis frequently accompanies diffuse systemic disorders, particularly psoriatic arthritis and spondyloarthropathies.[4]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Enthesopathies can be classified into 2 broad categories: (1) repetitive mechanical stress and (2) diffuse inflammatory processes. Enthesopathies caused by repetitive mechanical stress are common in sports-related injuries, including lateral and medial epicondylitis and Achilles and shoulder enthesopathies. In contrast, diffuse inflammatory responses that lead to enthesopathies and enthesitis typically affect multiple entheses. Repetitive local microtrauma allows innate immune cells to infiltrate the area and trigger inflammation by releasing chemokines.[5] Chemokines involved in the local inflammatory response include C-X-C motif chemokine ligand 1 (CXCL1), C-C motif chemokine ligand 2 (CCL2), IL-17, tumor necrosis factor (TNF)-α, and prostaglandin E2 (PGE2).[3][5]
Epidemiology
The prevalence and incidence of enthesopathies associated with diffuse inflammatory disease are difficult to assess because of the varied nature, presentation, and etiology of these conditions.[6] Reports indicate that the prevalence of enthesitis in patients with psoriatic arthritis is approximately 35%.[7] Among patients with spondyloarthropathies, 10% to 60% have enthesitis.[6]
Pathophysiology
Enthesopathies can arise from multiple pathologic processes, including edema-related disruption of collagen fibers, mineralization progressing to calcification or ossification, diffuse inflammatory activity, and collagen reorganization that produces a thickened enthesis.[8] In some cases, enthesopathies develop as enthesophytes, which are new osseous outgrowths seen in disorders such as seronegative spondyloarthropathies, diabetes mellitus, localized trauma, and calcium pyrophosphate deposition disease.[9] Among these factors, mechanical stress is often the central initiator of the inflammatory cascade underlying enthesopathic change,[10] with lateral or medial epicondylitis serving as clinical examples.
Focal and systemic mechanisms contribute to disease evolution. Repetitive microtrauma at the enthesis activates innate immune pathways and chemokine signaling, stimulating the production of cytokines, including IL-1β, IL-17, TNF-α, and prostaglandin E2, as well as matrix metalloproteinases. These inflammatory mediators drive tenocyte apoptosis, matrix disruption, and T cell recruitment via signaling by C-X-C motif chemokine ligand 1 and C-C motif chemokine ligand 2.[8] In systemic inflammatory arthropathies such as psoriatic arthritis and spondyloarthropathies, mechanical loading may act as a lower-threshold trigger for these immune events.[10] The immune cell milieu within enthesopathic tissue closely mirrors that of chronic rheumatic and musculoskeletal conditions, reinforcing the bidirectional relationship between biomechanical stress and inflammation.[11]
Histopathology
Mucoid degeneration is the most consistent finding, characterized by increased extracellular matrix, disorganized collagen fibers, and sometimes chondroid metaplasia. On ultrasonography, these changes typically correspond to a hypoechoic, thickened tendon or enthesis with loss of the normal fibrillar echotexture and blurring of the tendon–bone interface. Inflammation is generally minimal, with only about 20% of studies reporting inflammatory cell infiltrates. Power Doppler or color Doppler findings may reveal mild to moderate hyperemia in a minority of cases, reflecting neovascularization rather than overt inflammatory hypervascularity. Increased vascularity is frequently observed, although assessment methods vary. Mucoid and vascular changes reflect a degenerative process rather than a purely inflammatory one, supporting the concept that enthesopathy is often related to aging and mechanical stress rather than acute injury.[12]
In specific disease contexts, such as spondyloarthropathies or psoriatic arthritis, inflammatory cell infiltrates (predominantly CD8+ T cells), osteoclastic bone resorption, and fibrocartilage destruction may be seen, sometimes accompanied by pannus formation and new bone growth.[13] Ultrasonography findings in these cases often include a marked Doppler signal at the enthesis, cortical bone irregularity or erosions, and hypoechoic thickening extending into adjacent soft tissue, sometimes with associated enthesophyte formation or bursal effusion. Chronic inflammation can lead to granulation tissue and eventual replacement of eroded annular fibers by bone.[12]
History and Physical
The history and physical examination for enthesopathies depend on the location of the affected entheses. The patient may report decreased range of motion of the affected area and localized pain. Inspection may reveal localized swelling or erythema. Pain may be elicited by palpating the affected area and moving the affected joint. Range of motion should be assessed both actively and passively to identify mechanical deficits and pain-related limitations. If a diffuse inflammatory disease is suspected, a more thorough physical examination should include evaluation of commonly affected areas, such as the sacroiliac joints, Achilles tendon, and distal interphalangeal joints. Moreover, a broad review of systems may reveal underlying causes of enthesitis, such as weight loss, night sweats, chills, or other constitutional symptoms.[4]
Evaluation
The assessment and evaluation of enthesopathies require a thorough history and physical examination, tailored to the potential underlying cause. In cases of repetitive strain with low suspicion for inflammatory disease, the physical examination is the primary method of evaluation, with imaging reserved for specific circumstances. Radiography can detect bone abnormalities and calcifications, whereas ultrasonography and MRI are more effective for visualizing soft tissues, including the enthesis.[14]
Ultrasonography is especially valuable for identifying subclinical enthesopathies that may not be evident on physical examination, such as in individuals with psoriasis, in whom this modality can reveal early signs suggesting an increased risk of psoriatic arthritis.[12][15] Early ultrasonographic changes can be reversed with biologic treatments for psoriasis, potentially preventing the development of psoriatic arthritis.[16] In patients with psoriatic arthritis, the presence of neovascularity in asymptomatic entheses may serve as a vascular risk factor for disease progression.[17] Additionally, ultrasonography can detect enthesophytes, which have been linked to similar spinal changes.[14] For enthesopathies caused by widespread inflammation, laboratory tests such as complete blood count, human leukocyte antigen B27, rheumatoid factor, and autoimmune markers are used to help determine the cause, with imaging techniques applied similarly to those for enthesopathies resulting from repetitive use.[18]
Treatment / Management
Treatment depends on the underlying etiology. For an overuse enthesopathy, the mainstay of treatment is ice, rest, and nonsteroidal anti-inflammatory drugs for 7 to 10 days.[19] However, the use of nonsteroidal anti-inflammatory drugs is somewhat controversial in the acute period because these medications may inhibit healing by blunting the inflammatory response.[20] Adjunct therapies for enthesopathies include skilled physical therapy, glucocorticoid injections, topical nitrate therapy, and platelet-rich plasma.(A1)
Results from studies showed that skilled physical therapy improved pain, function, and active range of motion in a broad range of pathologies, including shoulder, hip, elbow, and Achilles enthesopathy.[21][22][23] From a biomechanical perspective, different joint-position exercises may impose alternative stress on the tendon, which is theorized to stimulate healing after an injury.[24] Although routinely used in clinical practice, glucocorticoid injections are somewhat controversial. Evidence does not clearly support their use.[25] Moreover, glucocorticoid injections into the tendon are tenotoxic and may lead to further injury.[26](A1)
Topical nitrates are theorized to increase neovascularization, increase fibroblast activity, and promote collagen synthesis. Results from studies showed promising findings for topical glyceryl trinitrate as an adjunct therapy for chronic tendinopathies, including the wrist extensors, Achilles tendon, patellar tendon, and rotator cuff. Glyceryl trinitrate is available as a patch, with dosages ranging from 0.72 mg/d to 5 mg/d for tendinopathies.[27] Platelet-rich plasma is proposed to act by directly delivering a growth factor concentrate and creating a rich microenvironment that recruits additional cells and growth factors to promote healing. Although platelet-rich plasma continues to be studied, promising results suggest it may help with multiple enthesopathies, such as gluteal and elbow tendinopathies.[28][29](A1)
For calcific enthesopathies, a technique called barbotage can be used. Under direct visualization with ultrasonography or fluoroscopy, a calcific lesion is repeatedly injected with and aspirated through, typically with saline. Results from studies showed that this technique was effective in lateral epicondylopathy and rotator cuff calcific tendinitis.[30][31] Enthesopathies caused by diffuse inflammatory diseases can be treated with disease-modifying antirheumatic drugs, such as methotrexate and hydroxychloroquine. Additionally, biologics such as rituximab, etanercept, and infliximab may be used to target inflammatory markers and help reduce the overall disease burden.[32](B3)
Extracorporeal shock wave therapy has demonstrated efficacy in several enthesopathies, including plantar fasciitis, calcific tendinitis, and lateral epicondylitis, by promoting neovascularization, collagen synthesis, and tissue regeneration through mechanotransduction, with higher-dose focused regimens showing greater benefit.[33][34] When enthesopathies prove refractory to conservative measures, minimally invasive percutaneous ultrasonography-guided needle tenotomy devices such as Tenex (ultrasonic tissue debridement, Trice Medical) and TenJet (hydrosurgery-based tissue removal, HidroCision) offer an intermediate step; results from a meta-analysis of 35 studies found that percutaneous ultrasonography-guided needle tenotomy significantly improved pain and function with low complication rates, although rsults from a New England Journal of Medicine review noted that much of the evidence was derived from case series authored by device inventors or consultants.[35][36] When all conservative and minimally invasive treatments fail, typically after 12 months of unsuccessful treatment, surgical intervention remains an option; 80% to 90% of patients with lateral epicondylitis respond to nonsurgical treatment within 1 year, although for refractory cases, open or arthroscopic debridement has demonstrated high rates of pain resolution, and similar principles apply to insertional Achilles enthesopathy, where open debridement with augmentation may be required when more than 50% of the tendon is excised.[37][38](A1)
Differential Diagnosis
The differential diagnosis of enthesopathies can include avulsions, fractures, ligament or tendon rupture, localized infection, contusions, muscle strains, and malignant neoplasm.
Pertinent Studies and Ongoing Trials
A pivotal study in early psoriatic arthritis treatment, the Study of Etanercept and Methotrexate in Subjects with Psoriatic Arthritis (SEAM-PsA) trial, was a well-powered, double-blind study that compared the effectiveness of methotrexate, etanercept, and their combination in early psoriatic arthritis. The primary endpoint was the American College of Rheumatology 20% Response Criteria, with minimal disease activity as a secondary outcome. Results from the trial showed that both etanercept alone and combination therapy outperformed methotrexate monotherapy, with comparable results according to the American College of Rheumatology 20% Response Criteria and minimal disease activity across the etanercept groups.[9]
Researchers are investigating various stem cell types, including mesenchymal stem cells, adipose-derived stem cells, and bone marrow mesenchymal stem cells, for enthesis regeneration.[39] Results from animal studies showed that bone marrow mesenchymal stem cells combined with platelet-rich plasma promote growth factor production, enhance osteogenic differentiation, and improve biomechanical properties.[40] Despite these benefits, enthesis repair did not show significant improvements in structure or strength, likely due to the short study duration, as stem cells may need more time to fully regenerate tissue.[41]
Treatment Planning
Minimizing risk factors, such as chronic mechanical stress and specific patient characteristics, plays a significant role in the onset of enthesopathies. Results from a meta-analysis highlighted several risk factors that exacerbate severity, including female sex, smoking, obesity, diabetes mellitus, and hypercholesterolemia.[42] Conditions that affect gut permeability, such as celiac disease and inflammatory bowel disease, further increase susceptibility.[10] Additionally, the cytokine IL-23 may contribute to the progression of enthesopathies by amplifying the enthesial reaction to mechanical strain, leading to more frequent and severe manifestations.[18]
Prognosis
The prognosis of enthesopathies is generally favorable, depending on the underlying etiology. With adequate rest and rehabilitation, most cases of enthesopathies resolve within 2 to 4 weeks. Enthesopathies associated with diffuse inflammatory disease may result in prolonged recovery times, depending on the severity and etiology of the underlying disease.
Complications
The main complications of enthesopathies include chronic pain, functional impairment, structural damage, such as new bone formation and calcification, and reduced quality of life. Chronic inflammation at the enthesis can lead to bone spurs, which may result in restricted mobility and deformity.[43] Persistent pain and inflammation also contribute to significant functional limitations and disability, affecting daily activities and overall well-being.[43] Structural complications arise from ongoing inflammation and aberrant repair processes, including excessive vessel formation, bone deterioration, and altered fibrocartilage composition.[44] In spondyloarthropathies, enthesitis is a central driver of disease progression, leading to downstream joint damage and ankylosis.[45] Metabolic comorbidities (such as obesity and diabetes) can worsen enthesitis outcomes, resulting in more severe presentations and poorer responses to treatment.[13] Diagnostic challenges and potential misdiagnoses may delay appropriate treatment, further increasing the risk of complications.
Deterrence and Patient Education
Multiple subspecialties may encounter the initial presentation of enthesopathies, and an astute clinician must discern where the patient should be referred. Education for localized enthesopathies resulting from repetitive use can be safely provided in the clinician’s office or with a skilled physical or occupational therapist. Education about joint protective measures may also greatly benefit patients with overuse enthesopathies. For patients with an underlying systemic inflammatory disease, a more thorough and comprehensive educational approach may be necessary. Discussions with subspecialists such as physiatrists, rheumatologists, internists, and immunologists may be needed to adequately educate and treat select patients.
Enhancing Healthcare Team Outcomes
Enthesopathies involve pathologic changes at tendon and ligament insertion sites and arise from mechanical stress or diffuse inflammatory disease. Entheses stabilize joints and transmit mechanical forces, with fibrous types attaching to the periosteum and fibrocartilaginous types lacking periosteum. Degenerative changes commonly result from repetitive strain, whereas inflammatory forms occur in conditions such as psoriatic arthritis and spondyloarthropathies. Ultrasonography, MRI, and targeted physical examination support early identification by revealing hypoechogenicity, Doppler activity, cortical irregularity, or subclinical involvement. Treatment varies by etiology and may include rest, nonsteroidal anti-inflammatory drugs, physical therapy, biologics, or procedures such as platelet-rich plasma or barbotage.
Optimal patient-centered care requires clinicians across disciplines to integrate history, examination, and imaging findings to distinguish mechanical from inflammatory disease. Clinicians guide diagnostic strategy, coordinate laboratory testing, and select evidence-based treatments. Nurses assist with symptom assessment, patient education, and monitoring for progression or medication effects. Pharmacists support safe use of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biologics while reinforcing adherence. Interprofessional communication ensures timely referrals, accurate interpretation of imaging findings, and consistent monitoring, thereby improving functional outcomes, reducing complications, and strengthening overall team performance.
References
Sudoł-Szopińska I, Kwiatkowska B, Prochorec-Sobieszek M, Maśliński W. Enthesopathies and enthesitis. Part 1. Etiopathogenesis. Journal of ultrasonography. 2015 Mar:15(60):72-84. doi: 10.15557/JoU.2015.0006. Epub 2015 Mar 30 [PubMed PMID: 26674568]
Benjamin M, Toumi H, Ralphs JR, Bydder G, Best TM, Milz S. Where tendons and ligaments meet bone: attachment sites ('entheses') in relation to exercise and/or mechanical load. Journal of anatomy. 2006 Apr:208(4):471-90 [PubMed PMID: 16637873]
Araujo EG, Schett G. Enthesitis in psoriatic arthritis (Part 1): pathophysiology. Rheumatology (Oxford, England). 2020 Mar 1:59(Suppl 1):i10-i14. doi: 10.1093/rheumatology/keaa039. Epub [PubMed PMID: 32159793]
Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D. Enthesitis: from pathophysiology to treatment. Nature reviews. Rheumatology. 2017 Nov 21:13(12):731-741. doi: 10.1038/nrrheum.2017.188. Epub [PubMed PMID: 29158573]
Cambré I, Gaublomme D, Burssens A, Jacques P, Schryvers N, De Muynck A, Meuris L, Lambrecht S, Carter S, de Bleser P, Saeys Y, Van Hoorebeke L, Kollias G, Mack M, Simoens P, Lories R, Callewaert N, Schett G, Elewaut D. Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis. Nature communications. 2018 Nov 5:9(1):4613. doi: 10.1038/s41467-018-06933-4. Epub 2018 Nov 5 [PubMed PMID: 30397205]
Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Annals of the rheumatic diseases. 2000 Dec:59(12):985-94 [PubMed PMID: 11087703]
Polachek A, Li S, Chandran V, Gladman DD. Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. Arthritis care & research. 2017 Nov:69(11):1685-1691. doi: 10.1002/acr.23174. Epub 2017 Sep 21 [PubMed PMID: 27998023]
Garcia-Melchor E, Cafaro G, MacDonald L, Crowe LAN, Sood S, McLean M, Fazzi UG, McInnes IB, Akbar M, Millar NL. Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. Annals of the rheumatic diseases. 2021 Aug:80(8):1075-1085. doi: 10.1136/annrheumdis-2020-219335. Epub 2021 Mar 10 [PubMed PMID: 33692018]
Merola JF, Ogdie A. SEAM-PsA: Seems Like Methotrexate Works in Psoriatic Arthritis? Arthritis & rheumatology (Hoboken, N.J.). 2019 Jul:71(7):1027-1029. doi: 10.1002/art.40872. Epub [PubMed PMID: 30816631]
Husic R, Lackner A, Kump PK, Högenauer C, Graninger W, Dejaco C. High Prevalence of Ultrasound Verified Enthesitis in Patients With Inflammatory Bowel Disease With or Without Spondylarthritis. Frontiers in medicine. 2021:8():637459. doi: 10.3389/fmed.2021.637459. Epub 2021 Feb 12 [PubMed PMID: 33644102]
Crowe LAN, Akbar M, de Vos RJ, Kirwan PD, Kjaer M, Pedret C, McInnes IB, Siebert S, Millar NL. Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine? The Lancet. Rheumatology. 2023 May:5(5):e293-e304. doi: 10.1016/S2665-9913(23)00074-7. Epub [PubMed PMID: 38251592]
Bruni DF, Pierson SR, Sarwar F, Ring D, Ramtin S. Are the Pathologic Features of Enthesopathy, Tendinopathy, and Labral and Articular Disc Disease Related to Mucoid Degeneration? A Systematic Review. Clinical orthopaedics and related research. 2023 Apr 1:481(4):641-650. doi: 10.1097/CORR.0000000000002499. Epub 2022 Dec 23 [PubMed PMID: 36563131]
Level 1 (high-level) evidenceLisco G, De Tullio A, Zupo R, Prete M, Piazzolla G, Racanelli V, Triggiani V. Metabolic-associated enthesitis: a review on pathophysiology, clinical relevance, diagnostic challenges, and perspective on target treatments. Immunologic research. 2025 Jul 11:73(1):106. doi: 10.1007/s12026-025-09655-0. Epub 2025 Jul 11 [PubMed PMID: 40646307]
Level 3 (low-level) evidenceRuyssen-Witrand A, Jamard B, Cantagrel A, Nigon D, Loeuille D, Degboe Y, Constantin A. Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD open. 2017:3(2):e000482. doi: 10.1136/rmdopen-2017-000482. Epub 2017 Sep 7 [PubMed PMID: 28955496]
Rothschild BM. Clinical implications of reconsideration of enthesitis/enthesopathy/enthesial erosion, as tendon attachment-localized avulsions and stress fracture equivalents. World journal of orthopedics. 2024 Oct 18:15(10):902-907. doi: 10.5312/wjo.v15.i10.902. Epub 2024 Oct 18 [PubMed PMID: 39473521]
Urruticoechea-Arana A, Moreno M, Pujol M, Clavaguera T. Ultrasound in the Evaluation of Dactylitis and Enthesitis in Psoriatic Arthritis. European journal of rheumatology. 2024 Jan 18:11(3):S298-S304. doi: 10.5152/eurjrheum.2024.21096. Epub [PubMed PMID: 39311552]
Aydin SZ, Ash ZR, Tinazzi I, Castillo-Gallego C, Kwok C, Wilson C, Goodfield M, Gisondi P, Tan AL, Marzo-Ortega H, Emery P, Wakefield RJ, McGonagle DG. The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development. Annals of the rheumatic diseases. 2013 Jun:72(6):992-5. doi: 10.1136/annrheumdis-2012-201617. Epub 2012 Aug 3 [PubMed PMID: 22863575]
Sayampanathan AA, Basha M, Mitra AK. Risk factors of lateral epicondylitis: A meta-analysis. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 2020 Apr:18(2):122-128. doi: 10.1016/j.surge.2019.08.003. Epub 2019 Sep 19 [PubMed PMID: 31543312]
Level 1 (high-level) evidenceLian J, Mohamadi A, Chan JJ, Hanna P, Hemmati D, Lechtig A, Nazarian A. Comparative Efficacy and Safety of Nonsurgical Treatment Options for Enthesopathy of the Extensor Carpi Radialis Brevis: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. The American journal of sports medicine. 2019 Oct:47(12):3019-3029. doi: 10.1177/0363546518801914. Epub 2018 Oct 31 [PubMed PMID: 30380334]
Level 1 (high-level) evidenceRees JD, Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. Rheumatology (Oxford, England). 2006 May:45(5):508-21 [PubMed PMID: 16490749]
Level 3 (low-level) evidenceFrizziero A, Vittadini F, Pignataro A, Gasparre G, Biz C, Ruggieri P, Masiero S. Conservative management of tendinopathies around hip. Muscles, ligaments and tendons journal. 2016 Jul-Sep:6(3):281-292. doi: 10.11138/mltj/2016.6.3.281. Epub 2016 Dec 21 [PubMed PMID: 28066732]
Smidt N, van der Windt DA, Assendelft WJ, Devillé WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet (London, England). 2002 Feb 23:359(9307):657-62 [PubMed PMID: 11879861]
Level 1 (high-level) evidenceSussmilch-Leitch SP, Collins NJ, Bialocerkowski AE, Warden SJ, Crossley KM. Physical therapies for Achilles tendinopathy: systematic review and meta-analysis. Journal of foot and ankle research. 2012 Jul 2:5(1):15. doi: 10.1186/1757-1146-5-15. Epub 2012 Jul 2 [PubMed PMID: 22747701]
Level 1 (high-level) evidenceMaganaris CN, Narici MV, Almekinders LC, Maffulli N. Biomechanics and pathophysiology of overuse tendon injuries: ideas on insertional tendinopathy. Sports medicine (Auckland, N.Z.). 2004:34(14):1005-17 [PubMed PMID: 15571430]
Speed CA. Fortnightly review: Corticosteroid injections in tendon lesions. BMJ (Clinical research ed.). 2001 Aug 18:323(7309):382-6 [PubMed PMID: 11509432]
Level 1 (high-level) evidenceFredberg U. Local corticosteroid injection in sport: review of literature and guidelines for treatment. Scandinavian journal of medicine & science in sports. 1997 Jun:7(3):131-9 [PubMed PMID: 9200316]
Challoumas D, Kirwan PD, Borysov D, Clifford C, McLean M, Millar NL. Topical glyceryl trinitrate for the treatment of tendinopathies: a systematic review. British journal of sports medicine. 2019 Feb:53(4):251-262. doi: 10.1136/bjsports-2018-099552. Epub 2018 Oct 9 [PubMed PMID: 30301735]
Level 1 (high-level) evidenceLee JJ, Harrison JR, Boachie-Adjei K, Vargas E, Moley PJ. Platelet-Rich Plasma Injections With Needle Tenotomy for Gluteus Medius Tendinopathy: A Registry Study With Prospective Follow-up. Orthopaedic journal of sports medicine. 2016 Nov:4(11):2325967116671692 [PubMed PMID: 27868077]
Kwapisz A, Prabhakar S, Compagnoni R, Sibilska A, Randelli P. Platelet-Rich Plasma for Elbow Pathologies: a Descriptive Review of Current Literature. Current reviews in musculoskeletal medicine. 2018 Dec:11(4):598-606. doi: 10.1007/s12178-018-9520-1. Epub [PubMed PMID: 30255288]
Abate M, Salini V, Schiavone C. Ultrasound-guided Percutaneous Lavage in the Treatment of Calcific Tendinopathy of Elbow Extensor Tendons: A Case Report. Malaysian orthopaedic journal. 2016 Jul:10(2):53-55. doi: 10.5704/MOJ.1607.011. Epub [PubMed PMID: 28435563]
Level 3 (low-level) evidenceBurke CJ, Adler RS. Ultrasound-Guided Percutaneous Tendon Treatments. AJR. American journal of roentgenology. 2016 Sep:207(3):495-506. doi: 10.2214/AJR.16.16089. Epub 2016 May 25 [PubMed PMID: 27224839]
Rizzello F, Olivieri I, Armuzzi A, Ayala F, Bettoli V, Bianchi L, Cimino L, Costanzo A, Cristaudo A, D'Angelo S, Daperno M, Fostini AC, Galeazzi M, Gilio M, Gionchetti P, Gisondi P, Lubrano E, Marchesoni A, Offidani A, Orlando A, Pugliese D, Salvarani C, Scarpa R, Vecchi M, Girolomoni G. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in therapy. 2018 Apr:35(4):545-562. doi: 10.1007/s12325-018-0672-6. Epub 2018 Mar 7 [PubMed PMID: 29516409]
Level 3 (low-level) evidenceWu KT, Chou WY, Wang CJ, Chen CY, Ko JY, Chen PC, Cheng JH, Yang YJ. Efficacy of Extracorporeal Shockwave Therapy on Calcified and Noncalcified Shoulder Tendinosis: A Propensity Score Matched Analysis. BioMed research international. 2019:2019():2958251. doi: 10.1155/2019/2958251. Epub 2019 Mar 14 [PubMed PMID: 31001553]
Speed C. A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence. British journal of sports medicine. 2014 Nov:48(21):1538-42. doi: 10.1136/bjsports-2012-091961. Epub 2013 Aug 5 [PubMed PMID: 23918444]
Level 1 (high-level) evidenceMaag L, Linder S, Hackett L, Mitchkash M, Farley T, Lamar D, Fisher N, Burnham B. Effectiveness of Percutaneous Needle Tenotomy for Tendinopathies: A Systematic Review. Sports health. 2025 Jul:17(4):834-842. doi: 10.1177/19417381241275659. Epub 2024 Sep 5 [PubMed PMID: 39238190]
Level 1 (high-level) evidenceShomal Zadeh F, Shafiei M, Shomalzadeh M, Pierce J, Thurlow PC, Chalian M. Percutaneous ultrasound-guided needle tenotomy for treatment of chronic tendinopathy and fasciopathy: a meta-analysis. European radiology. 2023 Oct:33(10):7303-7320. doi: 10.1007/s00330-023-09657-2. Epub 2023 May 6 [PubMed PMID: 37148349]
Level 1 (high-level) evidenceGregory BP, Wysocki RW, Cohen MS. Controversies in Surgical Management of Recalcitrant Enthesopathy of the Extensor Carpi Radialis Brevis. The Journal of hand surgery. 2016 Aug:41(8):856-9. doi: 10.1016/j.jhsa.2016.06.010. Epub [PubMed PMID: 27491631]
Williams SK, Brage M. Heel pain-plantar fasciitis and Achilles enthesopathy. Clinics in sports medicine. 2004 Jan:23(1):123-44 [PubMed PMID: 15062587]
Rak Kwon D, Jung S, Jang J, Park GY, Suk Moon Y, Lee SC. A 3-Dimensional Bioprinted Scaffold With Human Umbilical Cord Blood-Mesenchymal Stem Cells Improves Regeneration of Chronic Full-Thickness Rotator Cuff Tear in a Rabbit Model. The American journal of sports medicine. 2020 Mar:48(4):947-958. doi: 10.1177/0363546520904022. Epub [PubMed PMID: 32167836]
Han L, Fang WL, Jin B, Xu SC, Zheng X, Hu YG. Enhancement of tendon-bone healing after rotator cuff injuries using combined therapy with mesenchymal stem cells and platelet rich plasma. European review for medical and pharmacological sciences. 2019 Oct:23(20):9075-9084. doi: 10.26355/eurrev_201910_19310. Epub [PubMed PMID: 31696498]
Nourissat G, Diop A, Maurel N, Salvat C, Dumont S, Pigenet A, Gosset M, Houard X, Berenbaum F. Mesenchymal stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model. PloS one. 2010 Aug 18:5(8):e12248. doi: 10.1371/journal.pone.0012248. Epub 2010 Aug 18 [PubMed PMID: 20805884]
Heming EE, Gibson ES, Friesen KB, Martin CL, Martin M, Asker M, Blauwet C, Bullock GS, Fredriksen H, Galarneau JM, Hayden KA, Lee JH, Mosler AB, Myklebust G, Pluim BM, Thornton JS, Whittaker JL, Whiteley R, Crossley KM, Møller M, Emery CA. Prevention strategies and modifiable risk factors for upper extremity injury: a systematic review and meta-analysis for the Female, woman and/or girl Athlete Injury pRevention (FAIR) consensus. British journal of sports medicine. 2025 Dec 3:59(22):1587-1598. doi: 10.1136/bjsports-2025-109907. Epub 2025 Dec 3 [PubMed PMID: 41135970]
Level 1 (high-level) evidencePing Seung O, Jia LP. Characteristics and Contributing Factors for Difficult to Treat Psoriatic Arthritis- a Comparative Analysis. Journal of psoriasis and psoriatic arthritis. 2025 Oct 29:():24755303251394308. doi: 10.1177/24755303251394308. Epub 2025 Oct 29 [PubMed PMID: 41181638]
Level 2 (mid-level) evidenceWang X, Xie L, Crane J, Zhen G, Li F, Yang P, Gao M, Deng R, Wang Y, Jia X, Fan C, Wan M, Cao X. Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease. The Journal of clinical investigation. 2018 Feb 1:128(2):846-860. doi: 10.1172/JCI96186. Epub 2018 Jan 22 [PubMed PMID: 29355842]
Khalil Jnyah M, Mezouar IE, Akasbi N, Harzy T. Pharmacological management of spondyloarthritis associated with inflammatory bowel disease: a systematic review of efficacy, safety, and emerging therapies. BMC rheumatology. 2025 Oct 22:9(1):125. doi: 10.1186/s41927-025-00559-y. Epub 2025 Oct 22 [PubMed PMID: 41126359]
Level 1 (high-level) evidence